National and International Trends in Tuberculosis. Edward Desmond Microbial Diseases Laboratory California Dept. of Public Health
|
|
- Albert Mathews
- 6 years ago
- Views:
Transcription
1 National and International Trends in Tuberculosis Edward Desmond Microbial Diseases Laboratory California Dept. of Public Health
2 Trend 1: The number of TB cases is decreasing In the USA (significantly), and Internationally (slightly)
3 Trend 2: Drug-resistant TB is on its way up Internationally, and Expected in the USA as a consequence where most TB is in the foreign-born
4 Trend 3: As higher percentages of U.S. TB cases are in the foreign-born, it becomes more urgent to support TB control in countries which are the source of immigration to the U.S. This includes international TB laboratory consultation New tools are available
5 Trend 4: Molecular methods enable rapid detection of drug-resistant TB GeneXpert is being used internationally GeneXpert and DNA sequencing are becoming a new standard of practice in the USA
6 Trend 5: DNA sequencing is revealing complexities of drug susceptibility and resistance which were not previously appreciated Studies linking DNA sequences with drug susceptibility/resistance are under way
7 Trend 1: TB Global Epidemiology WHO Report
8 Trends TB incidence in CA Year Case number Case rate , , Anticipated impact of Affordable Care Act Fewer uninsured Fewer patients for county TB clinics Decreased TB workload for county public health labs which serve those clinics
9 Trend 2: Higher percentage of U.S. TB cases are in the foreign-born
10 Trend 2, cont d Increasing proportion in TB is in the foreign-born increase in drug resistance is expected
11 Trend 3: increasingly, TB is in the foreign born. % MDR cases in U.S. 1.1% % MDR: Mexico 1.8% Philippines 5.6% India 4.3% Vietnam 3.7% China 6.4%
12 Trend 3, cont d Supporting TB control in countries which are the source of immigration to the U.S.: new guidance
13 No Stars (0 142 pts) < 55% 1 Star ( pts) 55 64% 2 Stars ( pts) 65 74% 3 Stars ( pts) 75 84% 4 Stars ( pts) 85 94% 5 Stars ( pts) 95% 95 % 5 Star % 4 Star % 3 Star % 2 Star % 1 Star <55 % 0 Star Stepwise Process
14 Audit Score Sheet Audit Score Sheet Section Total Points Section 1: Document and Records 25 Section 2: Management Reviews 17 Section 3: Organization and Personnel 20 Section 4: Client Management and Customer Service 8 Section 5: Equipment 30 Section 6: Internal audit 10 Section 7: Purchasing and Inventory 30 Section 8: Process Control and Internal and External Quality Assessment 33 Section 9: Information Management 18 Section 10: Corrective Action 12 Section 11: Occurrence/Incident Management and Process Improvement 12 Section 12: Facilities and Safety 43 TOTAL SCORE 258
15
16
17
18
19
20 Last slide for Trend 3, supporting TB control in countries which are the source of immigration to the U.S.
21 Trend 4: molecular methods enable rapid detection of drug-resistant TB Cepheid GeneXpert Combines sample preparation (using microfluidics) with real-time PCR Detects M. tb and predicts drug resistance (to rifampin as now configured) TB application now cleared by US FDA!
22 GeneXpert Cartridge Cover PCR Reaction Tube Liquid reservoirs Syringe Rotary valve Ultrasonic interface Base
23 Cepheid Gene Xpert, cont d Steingart, K., et al Cochrane Collaboration Report (metanalysis) For detecting M. tb, 88% sensitivity compared with culture (98% for smear + and 68% for smear neg) For detecting rifampin resistance, sensitivity of 94% and specificity of 98%
24 WHO endorsement for Cepheid GeneXpert for TB: Dec Use of GeneXpert could lead to a three-fold increase in the diagnosis of patients with drug-resistant TB and double the diagnosis of TB in people with HIV In high-burden countries, Cepheid will sell the instrument for about $17,000 and their reagent cost will be about $10 (USA price $60 to $70)
25 CDC guidelines for use of Cepheid GeneXpert MTB/RIF: MMWR 62(41): October 18, 2013 GeneXpert. instrument generated result MTB detected, RIF resistance detected MTB detected, RIF resistance not detected MTB detected, RIF resistance indeterminate MTB not detected Interpretation of Xpert MTB/RIF result MTB detected within sample, mutation in rpob detected MTB detected, but no mutation in rpob detected MTB detected, unable to determine if there is an rpob mutation MTB target is not detected within the sample Recommended minimum reporting language MTBC detected. A mutation in rpob has been detected, indicating possible rif resistance. Confirmatory testing should follow MTBC detected. No rpob mutation suggests probably RIF susceptible MTBC detected, presence of rpob gene mutations cannot be accurately determined MTBC not detected
26 Why do APHL and CDC recommend DNA sequencing each time GeneXpert detects an rpob mutation? In DNA sequencing performed at the MDL & CDC labs, 18-20% of the mutations found by GeneXpert are silent/ synonymous mutations which don t confer resistance This differs from studies performed in some high-burden countries where true resistance is much more prevalent Globally, the incidence of MDR TB is about 5 X higher than it is in the USA
27 GeneXpert MTBC Detection Performance DSHS-Austin 11/16/12-1/13/14 (1,178 sputum specimens) THANKS TO KEN JOST FROM TEXAS STATE LAB AFB Smear Positive Mtbc Reference Result Positive Negative Total 99% Accuracy Xpert Positive % Sensitivity Xpert Negative % Specificity Total % Prevalence 99% PPV 98% NPV AFB Smear Negative Mtbc Reference Result Positive Negative Total 98% Accuracy Xpert Positive % Sensitivity Xpert Negative % Specificity Total % Prevalence 89% PPV 98% NPV 27
28 GeneXpert Rifampin Resistance Performance DSHS-Austin Nov 2012 July 2014 (434 specimens) THANKS TO KEN JOST FROM TEXAS STATE LAB Rifampin Phenotype Resistant Susceptible Total 98% Accuracy Xpert Rifampin-R 9* 6** 15 90% Sensitivity Xpert Rifampin-S % Specificity Total % Prevalence 60% PPV 100% NPV 28
29 Specimen Probe rpob Mutation Texas RMP CDC RMP 1 A* No Amplification S - 2 B Phe514Phe S - 3 B Phe514Phe S S 4 B Phe514Phe S S 5 B Phe514Phe S S 6 B Asp516Tyr & Asp549Asn 7 C Ser522Leu R/S S** 8 D His526Tyr R R 9 D His526Asp R R 10 E Ser531Leu R R 11 E Ser531Leu R - 12 E Ser531Leu R - 13 E Ser531Leu R R S S THANKS TO KEN JOST FROM TEXAS STATE LAB Note that GXP probe B mutation was not associated with rifampin resistance. 14 E not tested R - 15 E Leu533Pro R/S S** 16 none Ile572Phe R S** 29
30 Why do APHL and CDC recommend DNA sequencing each time GeneXpert detects an rpob mutation? (cont d) Some rpob mutations are clinically significant, but TB strains with these mutations may test susceptible in MGIT DST More about this under trend 5
31 Rapid detection of second line drug resistance at CDC laboratory 31 Uses DNA sequencing of genes associated with resistance to 1 st and 2 nd line drugs Turnaround time of 3-4 days Service available beginning in Sept. 2009
32 MDDR Service: 32 Drugs and Genes for Panel Drug RIF INH KAN AMK CAP FQ PZA EMB Gene(s) rpob inha, katg rrs, eis rrs rrs, tlya gyra pnca embb
33 33 MDDR Service: Testing Algorithm Entire molecular panel Routine agar proportion DST panel (INH, RIF, EMB, STR, FQ, AMK, KAN, CAP, ETH, PAS) and MGIT PZA
34 How does Pyrosequencing work? G Lin PSQ
35 Below are steps occur in pyrosequencer: 1. Incorporation of dntp generates ppi. 2. APS + ppi ATP, catalyzed by ATP sulfurylase. 3. Luciferin oxyluciferin, driven by ATP & catalyzed by luciferase. 4. Light released, proportional to dntp incorporated, recorded by CCD. 5. Apyrase degrades unincorporated dntp & ATP. When degradation is complete, another dntp is added. 6. Pyrogram shows sequential event of dntp incorporated. The peak level is proportional to dntps incorporated. G Lin PSQ
36 Hit 1: gyra resistant codon 94ggc Score: 100 Identities: 31/31 (100%) Query 1 CCACCCGCACGGCGACGCGTCGATCTACGGC 31 Library 1 CCACCCGCACGGCGACGCGTCGATCTACGGC 31 Hit 2: gyra susceptible Score: 94.3 Identities: 30/31 (97%) Query 1 CCACCCGCACGGCGACGCGTCGATCTACGGC 31 Library 1 CCACCCGCACGGCGACGCGTCGATCTACGAC 31 G Lin PSQ
37 Detection of Drug Resistance Mutations Drugs of interest: For XDR screening INH, RIF, KAN, AMK, CAP, fqs Targeted Genes katg, inha promoter for INH rpob for RIF rrs for KAN, AMK & CAP gyra for Quinolones G Lin PSQ
38 Note: PSQ is suitable for sequencing short DNA segments, up to 50 base pairs G Lin PSQ
39 G Lin PSQ
40 Line Probe Assays: not cleared by U.S. FDA, but endorsed by WHO: Hain GenoType MTBDRplus 1) DNA Extraction 3) Hybridization 2) Amplification by PCR 4) Evaluation
41 Examples of GenoType MTBDRplus Results
42 Hain Line Probe MTBDR plus: comparison with culture in LJ and drug suscept. testing Multi-site study published by Raizada et al, Feb in PLOS One 9(2):e88626 Compared Hain MTBDRplus results to the results of culture in LJ and drug susceptibility testing 248 acid-fast smear positive patients had both Hain line-probe assay and culture in LJ with drug susceptibility testing
43 Raizada 2014 study, continued For line probe assay, 6% did not yield a valid result because of not enough DNA or some technical problem For culture and drug susceptibility testing, 20% did not yield a positive result because of contamination of the culture or failure of the drug susceptibility testing LPA yielded more results (94%) than culture and drug susceptibility testing (80%)
44 Trend 5: DNA sequencing is revealing complexities of drug susceptibility and resistance which were not previously appreciated
45 Low level rifampin resistance Working definition for the purpose of this talk: Presence of a mutation in rpob, which causes a change in amino acid sequence, leading to an increase in MIC above that of the wild type, but <1 ug/ml in MGIT so that the culture will test as susceptible in MGIT
46 Reports of treatment failure associated with low level resistance continue Williamson IJTLD :216 3 New Zealand cases in which Cepheid GeneXpert detected rpob mutation, but culture tested susceptible to rif in MGIT Treatment failed in these 3 cases (all were INH-resistant) Mutations 516 Tyr and 526 Leu were assoc. w/ rifampin MICs of 0.25 and 0.5 respectively
47 Rifampin issues, cont d Greater use of GeneXpert MTB/RIF will increase discovery of low-level resistance -- (GeneXpert says resistant, MGIT says susceptible DNA sequencing) Expanded use of GeneXpert is recommended (see poster/talk by Lisa Pascopella) When there is low level resistance, e.g. MGIT/Xpert discrepancy or sequencing, treatment regimen may need to be modified Anecdotal evidence: rif may still make an important contribution to the treatment regimen
48 Low level rifampin resistance recap Category Rifampin resistant Low level resistance Presence of rpob mutation Expected GeneXpert result Resistant by agar proportion Resistant by MGIT Clinical expectation Yes Rif resistant Resistant Resistant Rifampin not useful Yes Rif resistant +/- Susceptible Rifampin activity reduced, but still may be useful. More research needed. Treatment may fail. Susceptible No Rifampin susceptible Susceptible Susceptible Reliable contribution of Rif to treatment regimen
49 Rifampin: does MGIT miss resistance? Early validation studies show good correlation of MGIT rifampin results with those obtained by agar proportion method or BACTEC 12B Horne Metanalysis: JCM 51:393. Pooled sensitivity of MGIT 960 in detecting rif resistance, compared with other reference methods: 98.2% (but in some studies the reference method was another broth culture technique, namely BACTEC 12B/460)
50 What to do about rifampin Strains with certain specific rpob mutations may test susceptible to rifampin in MGIT In Africa and Bangladesh, these mutations are associated with treatment failure In USA, clinical impact may be less, but often significant Encourage use of GeneXpert When rpob mutation is detected, recommend sequencing Report presence of suspected low level resistance with carefully chosen wording and referral to RTMCC or TBCB MDR service
51 Taking it to a new level Predicting quantitative drug susceptibility and response to different drugs with a class of drugs within a day by DNA sequencing
52 All Resistance SNPs are not Equal Number of Isolates WHO critical concentrati on (0.25mg/L) Cmax (~3.5 mg/l) gyra SNP Isolate MOX MIC (mg/l) 90 GTG 94 AAC
53 All Resistance SNPs are not Equal Number of Isolates WHO critical concentrati on (0.25mg/L) Isolate MOX MIC (mg/l) gyra SNP 90 GTG 94 AAC
54 All Resistance SNPs are not Equal Number of Isolates WHO critical concentra tion (1.0 mg/l) Cmax (~7 mg/l) rpob SNP 516 GTC 516 TAC 526 AAC 526 TAC 531 TTG Isolate RIF MIC (mg/l)
55 All Resistance SNPs are not Equal Number of Isolates WHO critical concentra tion (1.0 mg/l) rpob SNP 516 GTC 516 TAC 526 AAC 526 TAC 531 TTG Isolate RIF MIC (mg/l)
56 Rifabutin MICs associated with various rpob mutations Note rifampin MICs in red in column headings. RBU MIC (µg/ml) None 531 tcg ttg Rif >8 516 gac gtc Rif>8 rpob Mutation 526 cac ctc Rif cac ggc Rif =2 526 cac agc Rif = cac tgc Rif (RIF S) Total Samples
57 MOX MIC & Mutations in gyra MOX MIC (ug/ml) Mutations ( # of strains) 90gtg 94gcc 95acc 94ggc 91ccg 94cac 94tac % % % % % % % % Total # strains % 15% 15% 32.5% 5% 10% 2.5% Total # strains G Lin 57
58 Summary, taking it to a new level DNA sequencing results can be available within a day or two after a specimen arrives in the laboratory Sequencing can provide information beyond the susceptible or resistant results yielded by culture-based drug sus. Testing E.g. for moxifloxacin, sequencing can reveal that mox should be used despite resistance at the critical concentration and suggest MIC testing E.g. for rifamycins, sequencing can suggest some instances in which rifabutin could be used despite rifampin resistance, and for some mutations rifampin could still be a useful component of the Rx regimen
59 Thank you
Landscape and Language of Molecular Diagnostics for TB Drug Resistance
Landscape and Language of Molecular Diagnostics for TB Drug Resistance Purpose This module will provide: A brief overview of basic principles of molecular biology An introduction to mutations and their
More informationRapid molecular diagnosis of TB and drug-resistant TB
Rapid molecular diagnosis of TB and drug-resistant TB 2 nd European Advanced Course in Clinical Tuberculosis Amsterdam 2014 J. Domínguez Institut d Investigació Germans Trias i Pujol Universitat Autònoma
More informationConsiderations for Conventional Drug Susceptibility Testing and Molecular Detection of Drug Resistance
Considerations for Conventional Drug Susceptibility Testing and Molecular Detection of Drug Resistance Angela M Starks, PhD National TB Conference June 2013 National Center for HIV/AIDS, Viral Hepatitis,
More informationRole of Molecular Methods in Tuberculosis Diagnosis and Treatment
Role of Molecular Methods in Tuberculosis Diagnosis and Treatment Beverly Metchock, DrPH, D(ABMM) Team Lead, Reference Laboratory/Division of Tuberculosis Elimination June 2012 National Center for HIV/AIDS,
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Xie YL, Chakravorty S, Armstrong DT, et al. Evaluation of a
More informationLABORATORY METHODS: Tuberculosis Diagnosis. Specimen collection and transport. Collection and transport (2)
LABORATORY METHODS: Tuberculosis Diagnosis Ed Desmond Microbial Diseases Lab, Calif. Dept. of Public Health Richmond, CA (510) 412-3781 ed.desmond@cdph.ca.gov Specimen collection and transport Specimens
More informationRecent Approaches in Detection of Drug- Resistant Tuberculosis. Dr M Hanif Bacteriologist Laboratory Division New Delhi Tuberculosis Centre
Recent Approaches in Detection of Drug- Resistant Tuberculosis Dr M Hanif Bacteriologist Laboratory Division New Delhi Tuberculosis Centre Newer Diagnostic Methods for MDR TB Rapid Culture and DST using
More informationEvaluation of the BD BACTEC MGIT 320 for Detection of Mycobacteria and. Drug Susceptibility testing of Mycobacterium tuberculosis
JCM Accepts, published online ahead of print on 17 July 2013 J. Clin. Microbiol. doi:10.1128/jcm.01357-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 6 7 Evaluation
More informationPerspectives from a Public Health Laboratory
Perspectives from a Public Health Laboratory July 1, 2015 Kimberlee Musser, PhD Chief, Bacterial Diseases Wadsworth Center *I have no disclosures. July 1, 2015 2 Drug Resistant Tuberculosis is a Global
More informationPositioning of TB Diagnostics within a Tiered System Integrated Approach from Reference to District Laboratory. Giorgio Roscigno CEO FIND
Positioning of TB Diagnostics within a Tiered System Integrated Approach from Reference to District Laboratory Giorgio Roscigno CEO FIND Integrated Laboratory Network Definition An integrated laboratory
More informationAssessing quality-assured diagnoses made by TB laboratories
Assessing quality-assured diagnoses made by TB laboratories Quality-assured TB laboratory Objectives: at the end of the assessment reviewers should comment on the laboratory network and its structure;
More informationWhole Genome Sequencing for TB Diagnostics. Kimberlee Musser, PhD Chief, Bacterial Diseases Wadsworth Center
Whole Genome Sequencing for TB Diagnostics Kimberlee Musser, PhD Chief, Bacterial Diseases Wadsworth Center 900,000 sq. ft. state-of-the-art-facilities- 5 locations ~700 staff, >150 doctoral level scientists
More informationStool GeneXpert MTB/Rif Assay
Stool GeneXpert MTB/Rif Assay Standard Operating Procedure 1.0. Purpose The purpose of this standard operating procedure (SOP) is to detail the steps for correctly performing, interpreting, and documenting
More informationGDF Diagnostics. John Loeber Procurement Team Manager
GDF Diagnostics John Loeber Procurement Team Manager Joint UNICEF, UNFPA & WHO Meeting with Manufacturers and Suppliers Copenhagen, Denmark September 2013 1 GDF Diagnostics Overview 1. Standard Diagnostics
More informationCPTR title slide. Daniela M Cirillo San Raffaele Scientific Institute NDWG-Cochair
CPTR title slide Daniela M Cirillo San Raffaele Scientific Institute NDWG-Cochair Outline The global threat of Drug Resistant TB Actions to control MDR-TB Barriers to implement universal screening for
More informationRegional Laboratory Testing Algorithm
Regional Laboratory Testing Algorithm Angela M. St arks, Ph.D. Chief, Laboratory Branch Division of Tuberculosis Elimination Evelyn Tomokane Belau National Hospital Lab Republic of Palau National Center
More informationA cluster of MDR tuberculosis among asylum seekers in Switzerland and other European Countries
A cluster of MDR tuberculosis among asylum seekers in Switzerland and other European Countries Laboratory and Epidemiological Investigation Peter M. Keller, MD Deputy Head Swiss National Centre for Mycobacteria
More informationThe Roller Coaster of PZA
The Roller Coaster of PZA Ying Zhang, MD, PhD Department of Molecular Microbiology & Immunology Bloomberg School of Public Health Johns Hopkins University Email: yzhang@jhsph.edu The Fate of PZA and Interest
More informationAuthor s response to reviews
Author s response to reviews Title: PLASMID-BASED HIGH-RESOLUTION MELTING ANALYSIS FOR ACCURATE DETECTION OF RPOB MUTATIONS IN MYCOBACTERIUM TUBERCULOSIS ISOLATES FROM MOROCCAN PATIENTS Authors: El Mehdi
More informationGlobal Implementation of Xpert MTB/Rif
Global Implementation of Xpert MTB/Rif David H Persing, MD, PhD Chief Medical and Technology Officer Cepheid, Sunnyvale, CA, USA Consulting Professor of Pathology Stanford University, Stanford, CA, USA
More informationRapid diagnosis of drugresistant
Perspective Rapid diagnosis of drugresistant TB using line probe assays: from evidence to policy Expert Rev. Resp. Med. 2(5), 583 588 (2008) Daphne I Ling, Alice A Zwerling and Madhukar Pai Author for
More informationTB diagnostics: top 10 FAQs by test developers
13 November 2012 Kuala Lumpur TB diagnostics: top 10 FAQs by test developers Madhukar Pai, MD, PhD Associate Professor McGill University, Montreal madhukar.pai@mcgill.ca The TB dx landscape in 2012 is
More informationNoncommercial culture and drug-susceptibility testing methods for screening patients at risk for multidrugresistant.
Noncommercial culture and drug-susceptibility testing methods for screening patients at risk for multidrugresistant tuberculosis Policy statement March 2010 1 Contents Abbreviations Executive summary 1.
More informationTB Intensive Tyler, Texas December 2-4, 2008
TB Intensive Tyler, Texas December 2-4, 2008 Diagnosis of TB: Mycobacteria Laboratory Becky Wilson MS, BS, M.T. (ASCP) December 3, 2008 Diagnosis of TB: Mycobacteria Laboratory Becky Wilson MS, BS, M.T.
More informationUpdate on quality management using EQA and RemoteXpert
Update on quality management using EQA and RemoteXpert 1. Department of Molecular Medicine and Haematology, School of Pathology, Faculty of Health Science, and NHLS, South Africa 2. Management Sciences
More informationRapid First- and Second-Line Drug Susceptibility Assay for Mycobacterium tuberculosis Isolates by Use of Quantitative PCR
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 2011, p. 69 75 Vol. 49, No. 1 0095-1137/11/$12.00 doi:10.1128/jcm.01500-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Rapid First- and
More informationFor quantitative methylation and mutation analysis using Pyrosequencing technology in a 24-well format
ProductProfile PyroMark Q24 For quantitative methylation and mutation analysis using Pyrosequencing technology in a 24-well format The PyroMark Q24 uses proven Pyrosequencing technology for real-time,
More informationResistance in TB: UK and Global perspectives; Laboratory detection
Resistance in TB: UK and Global perspectives; Laboratory detection BMST Meeting Friday 16 th May 2014 Ian Laurenson Scottish Mycobacteria Reference Laboratory Royal Infirmary of Edinburgh Ian.Laurenson@nhslothian.scot.nhs.uk
More informationTitle: Use of mycobacteriophage qpcr on MGIT broths for a rapid tuberculosis antibiogram
JCM Accepts, published online ahead of print on 26 February 2014 J. Clin. Microbiol. doi:10.1128/jcm.03637-13 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 Title: Use of mycobacteriophage
More informationBeyond Xpert: The fastfollowers and the NAAT pipeline
Beyond Xpert: The fastfollowers and the NAAT pipeline David Boyle PATH dboyle@path.org 7 th July 2014 Adv. TB Dx Course McGill University Montreal The Emerging TB Dx technology Landscapes Annual or semi-annual
More informationPyrosequencing. Alix Groom
Pyrosequencing Alix Groom Pyrosequencing high-throughput CpG methylation analysis platform real-time, sequence-based detection and quantification % methylation at multiple adjacent CpG sites 80-100 bases
More informationDisease and selection in the human genome 3
Disease and selection in the human genome 3 Ka/Ks revisited Please sit in row K or forward RBFD: human populations, adaptation and immunity Neandertal Museum, Mettman Germany Sequence genome Measure expression
More informationMolecular Diagnostics at the Point of Need Interim Results (to Dec-17) 20 March 2018
Molecular Diagnostics at the Point of Need Interim Results (to Dec-17) 20 March 2018 2 Decentralising molecular diagnostics DOCUMENT INFORMATION The information contained in this document and made verbally
More informationPreface. The Global Plan to Stop TB anticipates the availability of new diagnostics, drugs and vaccines by 2015.
WHO Library Cataloguing-in-Publication Data : New laboratory diagnostic tools for tuberculosis control. 1.Tuberculosis - diagnosis. 2.Tuberculosis - prevention and control 3.Laboratory techniques and procedures
More informationbased Tuberculosis Recording and Reporting System in China
Web-based based Tuberculosis Recording and Reporting System in China National Center for Tuberculosis Control and Prevention, China-CDC CDC 11 March 2011 Overview Infectious Disease Surveillance System
More informationORIGINAL ARTICLE /j x
ORIGINAL ARTICLE 10.1111/j.1469-0691.2004.01034.x Single-nucleotide polymorphism-based differentiation and drug resistance detection in Mycobacterium tuberculosis from isolates or directly from sputum
More informationLine Probe Assays (LiPA)
Line Probe Assays (LiPA) Rev. 1 Pag. 1 di 5 Destinatari: Coordinatore, Tecnici e Studenti del Settore Genotipizzazione Micobatteri - EBP CONTENT 1. SCOPE 2. APPLICATION 3. DEFINITIONS AND ABBEVIATIONS
More informationDoris Hillemann,* Sabine Rüsch-Gerdes, and Elvira Richter
JOURNAL OF CLINICAL MICROBIOLOGY, June 2009, p. 1767 1772 Vol. 47, No. 6 0095-1137/09/$08.00 0 doi:10.1128/jcm.00081-09 Copyright 2009, American Society for Microbiology. All Rights Reserved. Feasibility
More informationCharacterization of katg and rpob gene mutations in Multi Drug Resistant Mycobacterium tuberculosis clinical isolates
ISSN: 2319-7706 Volume 3 Number 9 (2014) pp. 1072-1080 http://www.ijcmas.com Original Research Article Characterization of katg and rpob gene mutations in Multi Drug Resistant Mycobacterium tuberculosis
More informationStandard Operating Procedure (SOP) Specimen processing of CSF, lymph nodes and other tissues for Xpert MTB/RIF
Page: 1 of 7 Content 1. Scope 2. Definitions and abbreviations 3. Procedure 3.1 Principle 3.2 General considerations 3.3 Specimen processing 3.3.1 Lymph nodes and other tissues (Xpert MTB/RIF only) 3.3.2
More informationRapid Detection of rpob Gene Mutations in Rif-resistant M. tuberculosis Isolates by Oligonucleotide Microarray 1
BIOMEDICAL AND ENVIRONMENTAL SCIENCES 22, 253-258 (2009) www.besjournal.com Rapid Detection of rpob Gene Mutations in Rif-resistant M. tuberculosis Isolates by Oligonucleotide Microarray 1 AI-HUA SUN *,
More informationA Practical Handbook for National TB Laboratory Strategic Plan Development
A Practical Handbook for National TB Laboratory Strategic Plan Development TB CARE A Practical Handbook for National TB Laboratory Strategic Plan Development Second English Edition February 2014 International
More informationMaria Lina Rosilawati 1 and Andi Yasmon 2
DETECTION OF MULTIDRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS DIRECTLY FROM SPUTUM SAMPLES OF PATIENTS FROM JAKARTA, INDONESIA BY RADIOISOTOPE-BASED PCR-DOT BLOT HYBRIDIZATION Maria Lina Rosilawati 1 and
More informationHow to Choose the Right Equipment/Platforms for your Laboratory
How to Choose the Right Equipment/Platforms for your Laboratory (A Public Hospital Laboratory Perspective) Michelle J. Francis Overview Public Hospital Pressures / Challenges Commercial vs In-house assays
More informationSupranational Reference Laboratory and Private laboratories in RNTCP
Supranational Reference Laboratory and Private laboratories in RNTCP Facing the Reality of MDR-TB: Challenges and Potential Solutions in India New Delhi, India, 18-19 April 2011 N. Selvakumar Deputy Director
More informationSupplemental Data Supplemental Figure 1.
Supplemental Data Supplemental Figure 1. Silique arrangement in the wild-type, jhs, and complemented lines. Wild-type (WT) (A), the jhs1 mutant (B,C), and the jhs1 mutant complemented with JHS1 (Com) (D)
More informationBiosafety and Risk Assessment for New Molecular Methods
Biosafety and Risk Assessment for New Molecular Methods Michael Pentella, PhD, D(ABMM) Michael.pentella@state.ma.us Director, Massachusetts Bureau of Laboratory Sciences Disclosures Dr. Pentella has no
More informationREPUBLIC of MOLDOVA. Country experience. Title/Country. Presenter Title
REPUBLIC of MOLDOVA. Country experience Title/Country Presenter Title 6 th GLI Partners Meeting ROMANCENCO ELENA 30 April 2 May 2014 REPUBLIC of MOLDOVA Independent from 1991 Ex-Soviet Union country, in
More informationstrain devoid of the aox1 gene [1]. Thus, the identification of AOX1 in the intracellular
Additional file 2 Identification of AOX1 in P. pastoris GS115 with a Mut s phenotype Results and Discussion The HBsAg producing strain was originally identified as a Mut s (methanol utilization slow) strain
More informationTable S1. Bacterial strains (Related to Results and Experimental Procedures)
Table S1. Bacterial strains (Related to Results and Experimental Procedures) Strain number Relevant genotype Source or reference 1045 AB1157 Graham Walker (Donnelly and Walker, 1989) 2458 3084 (MG1655)
More informationHigh-Resolution Melting Curve Analysis for Rapid Detection of Rifampin and Isoniazid Resistance in Mycobacterium tuberculosis Clinical Isolates
JOURNAL OF CLINICAL MICROBIOLOGY, Nov. 2010, p. 3893 3898 Vol. 48, No. 11 0095-1137/10/$12.00 doi:10.1128/jcm.00396-10 Copyright 2010, American Society for Microbiology. All Rights Reserved. High-Resolution
More informationSupplement 1: Sequences of Capture Probes. Capture probes were /5AmMC6/CTG TAG GTG CGG GTG GAC GTA GTC
Supplementary Appendixes Supplement 1: Sequences of Capture Probes. Capture probes were /5AmMC6/CTG TAG GTG CGG GTG GAC GTA GTC ACG TAG CTC CGG CTG GA-3 for vimentin, /5AmMC6/TCC CTC GCG CGT GGC TTC CGC
More informationNontuberculous Mycobacteria
Nontuberculous Mycobacteria NTM diagnostics rapid, reliable and comprehensive! Our molecular genetic test systems for mycobacteria differentiation and drug susceptibility testing allow comprehensive information
More informationLecture 11: Gene Prediction
Lecture 11: Gene Prediction Study Chapter 6.11-6.14 1 Gene: A sequence of nucleotides coding for protein Gene Prediction Problem: Determine the beginning and end positions of genes in a genome Where are
More information3) Use of TST or QFT-G is recommended (not both). Persons with a documented prior positive TST or QFT-G result do not need to be retested.
Notes for Algorithms 1) Management of contacts to XDR-TB patients is complex and largely based on expert opinion. Individual patient decisions may need to vary from these algorithms based on individual
More informationSupporting Information. Copyright Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, 2006
Supporting Information Copyright Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, 2006 Copyright Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, 2006 Supporting Information for Expanding the Genetic
More informationSupplementary Materials for
www.sciencesignaling.org/cgi/content/full/10/494/eaan6284/dc1 Supplementary Materials for Activation of master virulence regulator PhoP in acidic ph requires the Salmonella-specific protein UgtL Jeongjoon
More informationTUBERCULOSIS Diagnostics Technology Landscape 5th Edition, May 2017
TUBERCULOSIS Diagnostics Technology Landscape 5th Edition, May 2017 2017 World Health Organization (Acting as the host organization for the Secretariat of Unitaid) The designations employed and the presentation
More informationMolecular Diagnostics for Global Heath Problems. Proactive Investors Forum 5 October 2017
Molecular Diagnostics for Global Heath Problems Proactive Investors Forum 5 October 2017 2 Document Information The information contained in this document and made verbally to you (together the Presentation
More informationIGRAs for Serial Testing of Healthcare Workers
IGRAs for Serial Testing of Healthcare Workers Jason Stout, MD, MHS Wake County TB Medical Consultant NC TB Medical Director Division of Infectious Diseases, Duke University Medical Center Disclosures-Funding
More informationFigure S1. Characterization of the irx9l-1 mutant. (A) Diagram of the Arabidopsis IRX9L gene drawn based on information from TAIR (the Arabidopsis
1 2 3 4 5 6 7 8 9 10 11 12 Figure S1. Characterization of the irx9l-1 mutant. (A) Diagram of the Arabidopsis IRX9L gene drawn based on information from TAIR (the Arabidopsis Information Research). Exons
More informationPublic private partnerships
THE INTERNATIONAL CONFERENCE ON (RE-)EMERGING INFECTIOUS DISEASES 14 March 2018 in Addis Ababa, Ethiopia Public private partnerships Engaging the private research sector to scale up infectious diseases
More informationBacktrack to a previous lecture: where do antibiotic resistance genes and alleles come from?
Biology 322 Lecture Nov 15, 2010 Anouncements: see course web site Backtrack to a previous lecture: where do antibiotic resistance genes and alleles come from? Thinking about the nature of mutation & about
More informationAdd 5µl of 3N NaOH to DNA sample (final concentration 0.3N NaOH).
Bisulfite Treatment of DNA Dilute DNA sample to 2µg DNA in 50µl ddh 2 O. Add 5µl of 3N NaOH to DNA sample (final concentration 0.3N NaOH). Incubate in a 37ºC water bath for 30 minutes. To 55µl samples
More informationSupplemental Data. mir156-regulated SPL Transcription. Factors Define an Endogenous Flowering. Pathway in Arabidopsis thaliana
Cell, Volume 138 Supplemental Data mir156-regulated SPL Transcription Factors Define an Endogenous Flowering Pathway in Arabidopsis thaliana Jia-Wei Wang, Benjamin Czech, and Detlef Weigel Table S1. Interaction
More informationElectronic Supplementary Information
Electronic Supplementary Material (ESI) for Molecular BioSystems. This journal is The Royal Society of Chemistry 2017 Electronic Supplementary Information Dissecting binding of a β-barrel outer membrane
More informationMycobacterial Culture
Mycobacterial Culture 1 Mycobacterial Culture OVERVIEW AND PURPOSE 2 Mycobacterial Culture Gold standard for sensitivity and specificity Use of culture increases the number of TB cases found by 30 50%
More informationSupplementary Figures. Figure S1. Design and operation of the microfluidic cartridge.
Supplementary Figures Figure S1. Design and operation of the microfluidic cartridge. (a) The device has three inlets for DNA and capture beads, MNP probes and washing buffer. Each inlet is gated by the
More information9th National Conference on Laboratory Aspects of Tuberculosis
9th National Conference on Laboratory Aspects of Tuberculosis Conference Program June 8 9, 2015 Schedule... p. xx Exhibitors... p. xx Posters... p. xx Attendees... p. xx Meeting at a Glance TIME 7:00am
More informationSAY IT WITH DNA: Protein Synthesis Activity by Larry Flammer
TEACHER S GUIDE SAY IT WITH DNA: Protein Synthesis Activity by Larry Flammer SYNOPSIS This activity uses the metaphor of decoding a secret message for the Protein Synthesis process. Students teach themselves
More informationThe TB diagnostic pipeline
The TB diagnostic pipeline Claudia Denkinger, MD PhD MSc DTMH Head of TB Programme at FIND 11th October 2017, Union Meeting, Guadalajara What are the diagnostic gaps in the care cascade? 1. Detect more
More informationA Verification Study for Implementing the Revised CLSI Breakpoints. Summary. Breakpoint Differences Cephalosporin Breakpoints for Enterobacteriaceae
A Verification Study for Implementing the Revised CLSI Breakpoints Jean B. Patel, PhD, D(ABMM) Deputy Director, Office of Antimicrobial Resistance National Center for Emerging and Zoonotic Infectious Disease
More informationA Verification Study for Implementing the Revised CLSI Breakpoints. Summary. Glossary CDC 1
A Verification Study for Implementing the Revised CLSI Breakpoints Jean B. Patel, PhD, D(ABMM) Deputy Director, Office of Antimicrobial Resistance National Center for Emerging and Zoonotic Infectious Disease
More informationAfranio Kritski. Medical School Federal University of Rio de Janeiro - Rede TB
Afranio Kritski. Medical School Federal University of Rio de Janeiro - Rede TB Outline 2015 Global End TB Strategy 2001-2016 Rede TB - Platforms Brazilian Response Role of RePORT Brazil Final Comments
More informationRapid Detection and Quantification of Mycobacterium Tuberculosis Using Single-Based Extension and Capillary Electrophoresis
University of Arkansas, Fayetteville ScholarWorks@UARK Biomedical Engineering Undergraduate Honors Theses Biomedical Engineering 5-2013 Rapid Detection and Quantification of Mycobacterium Tuberculosis
More informationInnovations in Molecular Lab Operation. Joseph M. Campos, PhD, D(ABMM), F(AAM)
Innovations in Molecular Lab Operation Lessons in the Best Ways to Blend Automation, Lean Workflow, and Paperless Processes Joseph M. Campos, PhD, D(ABMM), F(AAM) Interim Chief, Division of Laboratory
More informationShould IGRAs replace the TST?
Should IGRAs replace the TST? Jim Rothel Melbourne, Australia Disclaimer: I am a consultant to Cellestis, a QIAGEN company Presentation Outline Comparative performance of QFT and the TST Is the TST / QFT
More informationINTRODUCTION TO THE MOLECULAR GENETICS OF THE COLOR MUTATIONS IN ROCK POCKET MICE
The Making of the The Fittest: Making of the Fittest Natural Selection Natural and Adaptation Selection and Adaptation Educator Materials TEACHER MATERIALS INTRODUCTION TO THE MOLECULAR GENETICS OF THE
More informationII 0.95 DM2 (RPP1) DM3 (At3g61540) b
Table S2. F 2 Segregation Ratios at 16 C, Related to Figure 2 Cross n c Phenotype Model e 2 Locus A Locus B Normal F 1 -like Enhanced d Uk-1/Uk-3 149 64 36 49 DM2 (RPP1) DM1 (SSI4) a Bla-1/Hh-0 F 3 111
More informationMidterm 1 Results. Midterm 1 Akey/ Fields Median Number of Students. Exam Score
Midterm 1 Results 10 Midterm 1 Akey/ Fields Median - 69 8 Number of Students 6 4 2 0 21 26 31 36 41 46 51 56 61 66 71 76 81 86 91 96 101 Exam Score Quick review of where we left off Parental type: the
More informationGene mutation and DNA polymorphism
Gene mutation and DNA polymorphism Outline of this chapter Gene Mutation DNA Polymorphism Gene Mutation Definition Major Types Definition A gene mutation is a change in the nucleotide sequence that composes
More informationMycobacterium tuberculosis End-Point PCR Kit Product# EP42100
3430 Schmon Parkway Thorold, ON, Canada L2V 4Y6 Phone: 866-667-4362 (905) 227-8848 Fax: (905) 227-1061 Email: techsupport@norgenbiotek.com Mycobacterium tuberculosis End-Point PCR Kit Product# EP42100
More informationEngineering D66N mutant using quick change site directed mutagenesis. Harkewal Singh 09/01/2010
Engineering D66N mutant using quick change site directed mutagenesis Harkewal Singh 09/01/2010 1 1- What is quick change site directed mutagenesis? 2- An overview of the kit contents. 3- A brief information
More informationThe HLA Community s Success in Combining Clinical & Genomic Data
The HLA Community s Success in Combining Clinical & Genomic Data Elizabeth Trachtenberg MS, PhD, DABHI Director, Center for Applied Genomics HLA/Immunogenetics Laboratory Children s Hospital & Research
More information2014 APHL Next Generation Sequencing (NGS) Survey
APHL would like you to complete the Next Generation Sequencing (NGS) in Public Health Laboratories Survey. The purpose of this survey is to collect information on current capacities for NGS testing and
More informationXpert MTB/RIF test. Laboratory monitoring & evaluation tool Xpert Pre-handover Checklist
Xpert Pre-handover Checklist Part 1: Contact details Date of installation Facility name/ Laboratory name Contact details facility: Name, phone, email GeneXpert laboratory responsible Contact details Laboratory:
More informationRFP for Diagnostic Connectivity, Afghanistan
RFP for Diagnostic Connectivity, Afghanistan Challenge TB (CTB) is a global USAID-funded project, working in Afghanistan. CTB/Afghanistan is a five year project effective from January 2015-September 2019.
More informationN eisseria gonorrhoeae, a common causative agent of sexually
440 ORIGINAL ARTICLE Mutation patterns in gyra and parc genes of ciprofloxacin resistant isolates of Neisseria gonorrhoeae from India U Chaudhry, K Ray, M Bala, D Saluja... Sex Transm Infect 2002;78:440
More informationCodon Bias with PRISM. 2IM24/25, Fall 2007
Codon Bias with PRISM 2IM24/25, Fall 2007 from RNA to protein mrna vs. trna aminoacid trna anticodon mrna codon codon-anticodon matching Watson-Crick base pairing A U and C G binding first two nucleotide
More informationDevelopment of Sequence Based Molecular Diagnostic Test to Evaluate MDR and XDR in M. tuberculosis Patients from Western India
American Journal of Infectious Diseases and Microbiology, 2013, Vol. 1, No. 3, 50-58 Available online at http://pubs.sciepub.com/ajidm/1/3/3 Science and Education Publishing DOI:10.12691/ajidm-1-3-3 Development
More informationThe emergence of multidrug-resistant tuberculosis (MDR-TB)
SPECIAL ARTICLE Diagnosis of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: Current standards and challenges Giovanni Battista Migliori MD PhD 1, Alberto Matteelli MD PhD
More informationMolecular Diagnostics at the Point of Need
Molecular Diagnostics at the Point of Need 24 November 2016 David Budd CEO d.budd@genedrive.com 1 DOCUMENT INFORMATION The information contained in this document and made verbally to you (together the
More informationForecast diagnostics for antimicrobial resistance (AMR)
Forecast diagnostics for antimicrobial resistance (AMR) Authors: Ann Van den Bruel, Philip Turner NIHR Diagnostic Evidence Cooperative Oxford, University of Oxford Context When asked to make forecasts
More informationAlere q. A platform to answer global health needs: TB and beyond. Duncan Blair Director, Public Health Initiatives
Alere q A platform to answer global health needs: TB and beyond Duncan Blair Director, Public Health Initiatives 7 th FIND Symposium, Barcelona, October 2014 Alere q platform overview Comprising the Alere
More informationG+C content. 1 Introduction. 2 Chromosomes Topology & Counts. 3 Genome size. 4 Replichores and gene orientation. 5 Chirochores.
1 Introduction 2 Chromosomes Topology & Counts 3 Genome size 4 Replichores and gene orientation 5 Chirochores 6 7 Codon usage 121 marc.bailly-bechet@univ-lyon1.fr Bacterial genome structures Introduction
More informationand evolution University of St Andrews
Antimicrobial resistance: biology and evolution Stephen H. Gillespie University of St Andrews Overview Introduction, definitions and scope Acquisition of resistance Adaptation to resistance Transmission
More informationRequest for Proposal PRECLINICAL EVALUATION OF NEW DRUG COMBINATIONS AGAINST TUBERCULOSIS (RFP ) INTRODUCTION
Request for Proposal PRECLINICAL EVALUATION OF NEW DRUG COMBINATIONS AGAINST TUBERCULOSIS (RFP2006.01) The Global Alliance for TB Drug Development (the TB Alliance) is promoting a new paradigm for TB drug
More information